McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019:19 de septiembre. [Ref.ID 103194]

Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:1. [Ref.ID 103193]

Taylor P. J&J hit by $8bn judgment for man claiming breast growth due to Risperdal. PMLiVE 2019:9 de octubre. [Ref.ID 103192]

Dandjinou M, Sheehy O, Bérard A. Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case–control study. BMJ Open 2019;9:e025908. [Ref.ID 103190]

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med 2019:30 de julio. [Ref.ID 103183]

Taylor P. Servier faces manslaughter trial over weight loss drug deaths. Drug shown to damage heart and thought to cause death. PMLiVE 2019:24 de septiembre. [Ref.ID 103181]

Sainato M. Las farmacéuticas disparan el precio de la insulina y obligan a los estadounidenses a escoger entre techo o medicamentos . eldiario.es 2019:24 de septiembre. [Ref.ID 103180]

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. Eur J Clin Pharmacol 2019;75:837-47. [Ref.ID 103176]

Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Sumilo D, Thomas GN, Toulis KA, Nirantharakumar K. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ 2019;366:3 de septiembre. [Ref.ID 103172]

Andersen YMF, Egeberg A, Ban L, Gran S, Williams HC, Francis NA, Knop FK, Gislason GH, Skov L, Thyssen JP. Association between topical corticosteroid use and type 2 ciabetes in two European population-based adultcCohorts. Diabetes Care 2019;42:junio. [Ref.ID 103163]

Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]

Randolph AC, Lin Y-L, Volpi E, Kuo Y-F. Tricyclic antidepressant and/or ?-aminobutyric acid–analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103149]

Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RD, VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med 2019;380:6 de junio. [Ref.ID 103135]

Anónimo. Ginkgo biloba: to be avoided due to severe adverse effects. Prescrire Int 2019;28:155-6. [Ref.ID 103129]

Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Ospina NS, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ 2019;365:14 de mayo. [Ref.ID 103122]

Wei L, Lai EC-C, Kao-Yang Y-H, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5a-reductase inhibitors: population based cohort study. BMJ 2019;365:10 de abril. [Ref.ID 103112]

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium–glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 2019:7 de mayo. [Ref.ID 103108]

Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]